Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 10:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 449 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Heritable Pulmonary Arterial Hypertension Clear all
Completed Phase 3 Interventional Results available

BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension

NCT00863681
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Riociguat (BAY63-2521)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 80 Years
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
11
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 14, 2026, 10:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Food on the Pharmacokinetics of Oral Treprostinil

NCT00963001
View directory record Official record
Conditions
Hypertension, Pulmonary, Pulmonary Arterial Hypertension
Interventions
Treprostinil diethanolamine, Standardized meals
Drug · Other
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2010 · Synced Oct 14, 2026, 10:45 PM EDT
Terminated Phase 3 Interventional Results available

Clinical Study to Assess the Long-term Safety, Tolerability, and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome

NCT01739400
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Macitentan 10 mg tablet, once daily.
Drug
Lead sponsor
Actelion
Industry
Eligibility
12 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
5
States / cities
Atlanta, Georgia • St Louis, Missouri • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 14, 2026, 10:45 PM EDT
Completed No phase listed Observational

Modulating Effects of Lisinopril on Sildenafil Activity in Pulmonary Arterial Hypertension(PAH)( MELISSA)

NCT01181284
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 7, 2012 · Synced Oct 14, 2026, 10:45 PM EDT
Completed No phase listed Observational

The Expression and Significance of MiRNA

NCT00806312
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Not listed
Lead sponsor
Megan Ballinger
Other
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 14, 2026, 10:45 PM EDT
Terminated Phase 2 Interventional Results available

Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants

NCT05764265
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
LTP001
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Mesa, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 14, 2026, 10:45 PM EDT
Terminated Phase 2 Interventional Results available

Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH Patients

NCT02939599
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
QCC374
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 14, 2026, 10:45 PM EDT
Completed Phase 3 Interventional Results available

Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension

NCT03187678
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
i.v. selexipag, oral selexipag (Uptravi)
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
La Jolla, California • Boston, Massachusetts • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2025 · Synced Oct 14, 2026, 10:45 PM EDT
Completed Phase 1 Interventional Results available

Enteral L Citrulline Supplementation in Preterm Infants - Safety, Efficacy and Dosing

NCT03649932
View directory record Official record
Conditions
Bronchopulmonary Dysplasia, Bronchopulmonary Dysplasia Associated Pulmonary Hypertension, Pulmonary Hypertension, Premature Birth, Chronic Lung Disease of Prematurity
Interventions
Enteral L-citrulline
Dietary Supplement
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
Up to 30 Weeks
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 14, 2026, 10:45 PM EDT
Completed Phase 3 Interventional Results available

A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH)

NCT01824290
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Tadalafil, Placebo, ERA as specific PAH treatment
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Months to 17 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
7
States / cities
Atlanta, Georgia • Detroit, Michigan • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 14, 2026, 10:45 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

NCT06649110
View directory record Official record
Conditions
Healthy Volunteers, Pulmonary Arterial Hypertension
Interventions
LTP, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
232 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
19
States / cities
Scottsdale, Arizona • Orange, California • Stanford, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 14, 2026, 10:45 PM EDT
Terminated No phase listed Observational

Impact of Inhaled Treprostinil Sodium on Ventilation Perfusion Matching

NCT01494896
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Chronic Obstructive Pulmonary Disease
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
3
States / cities
Jacksonville, Florida • Weston, Florida
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced Oct 14, 2026, 10:45 PM EDT
Terminated Phase 2 Interventional

A Study of RVT-1201 in Patients With Pulmonary Arterial Hypertension (ELEVATE 1)

NCT03924154
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
RVT-1201, Placebo
Drug
Lead sponsor
Altavant Sciences GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
20
States / cities
Phoenix, Arizona • Sacramento, California • Santa Barbara, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 14, 2026, 10:45 PM EDT
Terminated Phase 4 Interventional

Inhaled Iloprost for the Treatment of Persistent Pulmonary Hypertension in the Term and Near Term Infants.

NCT00409526
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Inhaled Iloprost
Drug
Lead sponsor
University of Chicago
Other
Eligibility
Up to 7 Days
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 2, 2014 · Synced Oct 14, 2026, 10:45 PM EDT
Recruiting Phase 2 Interventional

Pulmonary Hypertension SOLAR

NCT04778046
View directory record Official record
Conditions
Interstitial Lung Disease, COPD, Pulmonary Arterial Hypertension
Interventions
Hyperpolarized 129Xe
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 14, 2026, 10:45 PM EDT
Completed Phase 4 Interventional Results available

Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication

NCT01268553
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
3
States / cities
Tucson, Arizona • San Francisco, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2017 · Synced Oct 14, 2026, 10:45 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Inhaled Nitric Oxide and Oxygen in Participants Reactivity During Acute Pulmonary Vasodilator Testing

NCT00626028
View directory record Official record
Conditions
Idiopathic Pulmonary Arterial Hypertension, Cardiomyopathy
Interventions
Nitric Oxide for inhalation, Oxygen, Nitric Oxide plus Oxygen
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
4 Weeks to 18 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
8
States / cities
Stanford, California • Denver, Colorado • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2019 · Synced Oct 14, 2026, 10:45 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension

NCT04175600
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Selexipag, Placebo, Standard of Care (SOC): Endothelin receptor antagonist, SOC: Phosphodiesterase type 5 (PDE-5) inhibitor, SOC: Soluble guanylate cyclase stimulator
Drug
Lead sponsor
Actelion
Industry
Eligibility
2 Years to 17 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
13
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 14, 2026, 10:45 PM EDT
Active, not recruiting Not applicable Interventional

Preductal Oxygen Saturation Target in Term and Late Preterm Neonates With Hypoxemic Respiratory Failure or Pulmonary Hypertension

NCT04938167
View directory record Official record
Conditions
Persistent Pulmonary Hypertension of the Newborn, Hypoxemic Respiratory Failure
Interventions
95% - 99% SpO2 target
Other
Lead sponsor
University of California, Davis
Other
Eligibility
0 Days to 28 Days
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 14, 2026, 10:45 PM EDT
Completed Phase 2 Interventional Results available

Anastrozole in Patients With Pulmonary Arterial Hypertension

NCT01545336
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Anastrozole, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
Philadelphia, Pennsylvania • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Oct 14, 2026, 10:45 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Hydroxyurea for Children and Young Adults With Sickle Cell Disease and Pulmonary Hypertension

NCT00350844
View directory record Official record
Conditions
Sickle Cell Disease, Pulmonary Hypertension
Interventions
Hydroxyurea
Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
10 Years to 25 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 14, 2026, 10:45 PM EDT
Completed Phase 1 Interventional Results available

Carnitine Consumption and Augmentation in Pulmonary Arterial Hypertension

NCT04908397
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Familial Primary Pulmonary Hypertension, Primary Pulmonary Hypertension, Lung Diseases, Carnitine Nutritional Deficiency
Interventions
L-carnitine
Dietary Supplement
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 14, 2026, 10:45 PM EDT
Completed Phase 4 Interventional

Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension

NCT00403650
View directory record Official record
Conditions
Sarcoidosis, Pulmonary Arterial Hypertension
Interventions
Iloprost
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 12, 2013 · Synced Oct 14, 2026, 10:45 PM EDT
Completed Phase 2 Interventional

Safety and Effectiveness of PRX-08066 in Patients With Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease

NCT00345774
View directory record Official record
Conditions
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Interventions
PRX-08066
Drug
Lead sponsor
Epix Pharmaceuticals, Inc.
Industry
Eligibility
25 Years to 79 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
19
States / cities
Anniston, Alabama • Phoenix, Arizona • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 29, 2008 · Synced Oct 14, 2026, 10:45 PM EDT